Correlation Between Climb Bio and Eupraxia Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Climb Bio and Eupraxia Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Climb Bio and Eupraxia Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Climb Bio and Eupraxia Pharmaceuticals Common, you can compare the effects of market volatilities on Climb Bio and Eupraxia Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Climb Bio with a short position of Eupraxia Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Climb Bio and Eupraxia Pharmaceuticals.

Diversification Opportunities for Climb Bio and Eupraxia Pharmaceuticals

-0.63

Correlation Coefficient

Climb Bio  Eupraxia Pharmaceuticals

Excellent diversification

The 3 months correlation between Climb and Eupraxia is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Climb Bio and Eupraxia Pharmaceuticals Commo in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eupraxia Pharmaceuticals and Climb Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Climb Bio are associated (or correlated) with Eupraxia Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eupraxia Pharmaceuticals has no effect on the direction of Climb Bio i.e., Climb Bio and Eupraxia Pharmaceuticals go up and down completely randomly.

Pair Corralation between Climb Bio and Eupraxia Pharmaceuticals

Given the investment horizon of 90 days Climb Bio is expected to under-perform the Eupraxia Pharmaceuticals. In addition to that, Climb Bio is 1.08 times more volatile than Eupraxia Pharmaceuticals Common. It trades about -0.17 of its total potential returns per unit of risk. Eupraxia Pharmaceuticals Common is currently generating about 0.04 per unit of volatility. If you would invest  264.00  in Eupraxia Pharmaceuticals Common on September 22, 2024 and sell it today you would earn a total of  35.00  from holding Eupraxia Pharmaceuticals Common or generate 13.26% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Climb Bio  vs.  Eupraxia Pharmaceuticals Commo

Climb Bio

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Climb Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Eupraxia Pharmaceuticals

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Climb Bio and Eupraxia Pharmaceuticals

The main advantage of trading using opposite Climb Bio and Eupraxia Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Climb Bio position performs unexpectedly, Eupraxia Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will offset losses from the drop in Eupraxia Pharmaceuticals' long position.

The idea behind Climb Bio and Eupraxia Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.